Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial

The Lancet

Volumn 390, Issue 10111, 2017, Pages 2481-2489

  Green, Ari J ^a   Gelfand, Jeffrey M ^a   Cree, Bruce A ^a   Bevan, Carolyn ^a   Boscardin, W John ^a   Mei, Feng ^a,b   Inman, Justin ^a   Arnow, Sam ^a   Devereux, Michael ^a   Abounasr, Aya ^a   Nobuta, Hiroko ^c   Zhu, Alyssa ^a   Friessen, Matt ^a   Gerona, Roy ^a   von Büdingen, Hans Christian ^a   Henry, Roland G ^a,b   Hauser, Stephen L ^a,b   Chan, Jonah R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEMASTINE FUMARATE; MYELIN; PLACEBO; CLEMASTINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LATENT PERIOD; MALE; MULTIPLE SCLEROSIS; OPTIC NERVE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMYELINIZATION; TREATMENT RESPONSE; VISUAL EVOKED POTENTIAL; DRUG EFFECT; OPTICAL COHERENCE TOMOGRAPHY; TREATMENT OUTCOME;

ADULT; CLEMASTINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; REMYELINATION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 85030841529     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32346-2     Document Type: Article

References (40)

1. Frohman, EM, Racke, MK, Raine, CS, Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med 354 (2006), 942–955.
2. Hauser, SL, Goodin, DS, Multiple sclerosis and other demyelinating diseases. In: Harrison's Principles of Internal Medicine. http://accessmedicine.mhmedical.com/content.aspx?bookid=331§ionid=40727196 (accessed Jan 4, 2016).
3. Emery, B, Regulation of oligodendrocyte differentiation and myelination. Science 330 (2010), 779–782.
4. Miron, VE, Kuhlmann, T, Antel, JP, Cells of the oligodendroglial lineage, myelination, and remyelination. Biochim Biophys Acta 1812 (2011), 184–193.
5. Czopka, T, Ffrench-Constant, C, Lyons, DA, Individual oligodendrocytes have only a few hours in which to generate new myelin sheaths in vivo. Dev Cell 25 (2013), 599–609.
6. Scolding, N, Franklin, R, Stevens, S, et al. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain 121 (1998), 2221–2228.
7. Wolswijk, G, Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 18 (1998), 601–609.
8. Kuhlmann, T, Miron, V, Cui, Q, Wegner, C, Antel, J, Brück, W, Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131 (2008), 1749–1758.
9. Périer, O, Grégoire, A, Electron microscopic features of multiple sclerosis lesions. Brain 88 (1965), 937–952.
10. Frischer, JM, Weigand, SD, Guo, Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 78 (2015), 710–721.
11. Hauser, SL, Chan, JR, Oksenberg, JR, Multiple sclerosis: prospects and promise. Ann Neurol 74 (2013), 317–327.
12. Brück, W, Gold, R, Lund, BT, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol 70 (2013), 1315–1324.
13. Polman, CH, Reingold, SC, Banwell, B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69 (2011), 292–302.
14. Lassmann, H, Brück, W, Lucchinetti, CF, The immunopathology of multiple sclerosis: an overview. Brain Pathol 17 (2007), 210–218.
15. Bjartmar, C, Trapp, BD, Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14 (2001), 271–278.
16. Waxman, SG, Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis. Trends Mol Med 12 (2006), 192–195.
17. Mei, F, Fancy, SP, Shen, YA, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med 20 (2014), 954–960.
18. Deshmukh, VA, Tardif, V, Lyssiotis, CA, et al. A regenerative approach to the treatment of multiple sclerosis. Nature 502 (2013), 327–332.
19. Mei, F, Lehmann-Horn, K, Shen, YA, et al. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife, 5, 2016, e18246.
20. Liu, J, Dupree, JL, Gacias, M, et al. Clemastine enhances myelination in the prefrontal cortex and rescues behavioral changes in socially isolated mice. J Neurosci 36 (2016), 957–962.
21. Li, Z, He, Y, Fan, S, Sun, B, Clemastine rescues behavioral changes and enhances remyelination in the cuprizone mouse model of demyelination. Neurosci Bull 31 (2015), 617–625.
22. Zada, D, Tovin, A, Lerer-Goldshtein, T, Appelbaum, L, Pharmacological treatment and BBB-targeted genetic therapy for MCT8-dependent hypomyelination in zebrafish. Dis Model Mech 9 (2016), 1339–1348.
23. Green, AJ, Visual evoked potentials, electroretinography, and other diagnostic approaches to the visual system. Aminoff, MJ, (eds.) Aminoff's electrodiagnosis in clinical neurology, 6th edn., 2012, Elsevier Saunders, Philadelphia, PA, 477–503.
24. Halliday, AM, McDonald, WI, Mushin, J, Visual evoked response in diagnosis of multiple sclerosis. BMJ 4 (1973), 661–664.
25. Toussaint, D, Perier, O, Verstappen, A, et al. Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuroophthalmol 3 (1983), 211–220.
26. Toosy, AT, Mason, DF, Miller, DH, Optic neuritis. Lancet Neurol 13 (2014), 83–99.
27. Horton, L, Conger, A, Conger, D, et al. Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology 80 (2013), 1862–1866.
28. Balcer, LJ, Frohman, EM, Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology 74:suppl 3 (2010), S16–S23.
29. Parmenter, BA, Weinstock-Guttman, B, Garg, N, Munschauer, F, Benedict, RH, Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. Mult Scler 13 (2007), 52–57.
30. Ray, PG, Meador, KJ, Loring, DW, et al. Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol 5 (1992), 72–77.
31. Dittner, AJ, Wessely, SC, Brown, RG, The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res 56 (2004), 157–170.
32. Schwartz, CE, Coulthard-Morris, L, Zeng, Q, Psychosocial correlates of fatigue in multiple sclerosis. Arch Phys Med Rehabil 77 (1996), 165–170.
33. Walsh, JC, Garrick, R, Cameron, J, McLeod, JG, Evoked potential changes in clinically definite multiple sclerosis: a two year follow up study. J Neurol Neurosurg Psychiatry 45 (1982), 494–500.
34. Niklas, A, Sebraoui, H, Hess, E, Wagner, A, Then Bergh, F, Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency. Mult Scler 15 (2009), 68–74.
35. Nuwer, MR, Packwood, JW, Myers, LW, et al. Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurology 37 (1987), 1754–1761.
36. Green, AJ, McQuaid, S, Hauser, SL, Allen, IV, Lyness, R, Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain 133 (2010), 1591–1601.
37. Hadjimichael, O, Vollmer, T, Oleen-Burkey, M, Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes, 6, 2008, 100.
38. Kubo, N, Shirakawa, O, Kuno, T, et al. Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn J Pharmacol 43 (1987), 277–282.
39. Cruce, R, Vosoughi, R, Freedman, MS, Cognitive impact of anticholinergic medication in MS: Adding insult to injury?. Mult Scler Relat Disord 1 (2012), 156–161.
40. Yeung, MS, Zdunek, S, Bergmann, O, et al. Dynamics of oligodendrocyte generation and myelination in the human brain. Cell 159 (2014), 766–774.